Adlyxin vs Xultophy

Drug comparison

Last updated 2026-05-28 15:46 UTC

Adlyxin (lixisenatide) and Xultophy (liraglutide) are both injectable medications for type 2 diabetes, made by Sanofi and Novo Nordisk respectively. Both are taken as a daily shot under the skin, but Adlyxin is a single ingredient while Xultophy combines two active drugs in one injection.

AI summary of the sources below.

	Adlyxin	Xultophy
Active ingredient	lixisenatide	liraglutide
Manufacturer	sanofi	novo-nordisk
Route	subcutaneous injection	subcutaneous injection
FDA-approved for	type 2 diabetes	type 2 diabetes
Label updated	—	2025-10-14

Compare full details on the Adlyxin and Xultophy pages.